Abstract:Abstract Pancreatic cancer is the third most common cause of death from cancer in the US. The disease has a poor prognosis with a five-year survival rate under 10%. Mutations in KRAS are driving tumor growth in about 95% of patients with pancreatic cancer. Currently there are no approved drugs that target KRAS. Recently there has been progress targeting a specific mutation, KRAS G12C with small molecules in lung cancer, but this mutation accounts for only 1% of patients with Pancreatic Ductal Adenocarcinoma (PDAC). RNA interference has the potential to directly target KRAS, but delivery to pancreas has been challenging. We have developed a lipid nanoparticle formulation that is able to distribute to pancreatic tumor tissue. The proprietary lipid nanoparticle (LNP) is comprised of an ionizable, non-immunogenic, biodegradable lipid and the composition has been tuned to favor enrichment in pancreatic tumor by screening in orthotopic pancreatic tumor mouse models. A potent siRNA with IC50 in the range of 10pM targeting KRAS directly has been identified and the activity on downstream pathways and kinetics have been demonstrated. Transfection of ND-05-1192 led to more impeded cell growth in pancreatic cancer cells (PANC-1, AsPC-1, Capan-1, SW1990 and BxPC-3) than normal cells (human hepatocyte, pancreatic cells and HUVEC cells). Western blot results demonstrated effective downregulations of key proteins involved in MAPK and PI3K signaling pathways and upregulated activities of proteins involved in apoptotic signaling pathways, such as BIM, caspase 3/7 and cleaved-PARP following inhibition of KRAS protein expression. In vivo biodistribution and tumor cell uptake study results demonstrated that LNP transported ND-05-1192 siRNA molecules to the pancreas site and pancreatic orthotopic tumor tissues with the majority of tumor cells showing LNP product uptake. The application of ND-05-1192/LNP product significantly suppressed tumor growth in PANC-1 and AsPC-1 bioluminescent orthotopic pancreatic xenograft models. Inhibition efficiency revealed by tumor weight and bioluminescent response (BLR) as the treatment end points reached up to 50% in the PANC-1 orthotopic xenografts following once weekly intravenous administration. In the orthotopic AsPC-1 model, the average BLR was significantly reduced in a dose-dependent manner. Additionally, in AsPC-1 orthotopic xenografts, the survival rate of the ND-05-1192/LNP treatment group was significantly prolonged at a 4 mg/kg dose compared to the vehicle control group. In summary, we conclude that ND-05-1192/LNP is delivered to the orthotopic pancreatic tumor and its considerable uptake by tumor cells results in KRAS target downregulation, tumor growth inhibition and overall survival benefit as demonstrated in our orthotopic xenograft models. Citation Format: Zhihong (Julie) OBrien, Li Wang, Cima Cina, Bharat Majeti, James Chu, Xiaoen Wang, Robiel Baclig, James Lin, Jose Ibarra, Dhrubamitra Chatterjee, Jung-Kang Jin, Jean-Pierre Clamme, Jennifer Daniels, Hai Wang, Jens Harborth, Wenbin Ying. Discovery and preclinical development of KRAS-targeting siRNA therapeutic modality for the treatment of pancreatic cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4060.

Lentivirus-mediated Short Hairpin RNA Targeting the APRIL Gene Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo

Targeting X-linked Inhibitor of Apoptosis Protein Inhibits Pancreatic Cancer Cell Growth Through P-Akt Depletion.

Lentivirus-mediated Shrna Targeting XIAP and Survivin Inhibit SW1990 Pancreatic Cancer Cell Proliferation in Vitro and in Vivo.

Preparation and purification of siRNA targeting a proliferation-inducing ligand of pancreatic cancer cell line

The experimental study of short hairpin RNA on the suppression of lung cancer-associated gene

Anti-angiogenesis by Lentivirus-Mediated Small Interfering RNA Silencing of Angiopoietin-2 Gene in Pancreatic Carcinoma

Silencing of Keratin 17 by Lentivirus-Mediated Short Hairpin RNA Inhibits the Proliferation of PANC-1 Human Pancreatic Cancer Cells.

RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research

The Study of Specific Inhibition of Mutant K-ras Gene Expression by Short Interfering RNAs in Human Pancreatic Carcinoma Cell PANC-1

Mechanism underlying drug resistance of HepG2/ADM cells silently reversed by lentivirus-mediated BC047440 gene during chemotherapy

Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model

Intratumoral injection of recombinant lentivirus-mediated Bmi1-shRNA inhibits growth of A549 xenografts in mice

Modulating drug resistance by targeting BCRP/ABCG2 using retrovirus-mediated RNA interference.

Promoted cancer growth by stimulating cell proliferation and decreasing apoptosis using a lentivirus-based EphB2 RNAi in pancreatic carcinoma CFPAC-1 cells.

Effects of IGF1R Sirna on Chemosensitivity to Gemcitabine in Human Pancreatic Cancer Cells

[Shrna-Mediated Insulin-Like Growth Factor I Receptor Gene Silencing Inhibits Cell Proliferation, Induces Cell Apoptosis, and Suppresses Tumor Growth in Non-Small Cell Lung Cancer: in Vitro and in Vivo Experiments].

Down-Regulation of Igf-Ir Using Small, Interfering, Hairpin Rna (sirna) Inhibits Growth of Human Lung Cancer Cell Line A549 in Vitro and in Nude Mice

NRP-1 silencing suppresses hepatocellular carcinoma cell growth in vitro and in vivo.

Abstract 4060: Discovery and preclinical development of KRAS-targeting siRNA therapeutic modality for the treatment of pancreatic cancer

Suppression of Type 1 Insulin-Like Growth Factor Receptor Expression by Small Interfering Rna Inhibits A549 Human Lung Cancer Cell Invasion in Vitro and Metastasis in Xenograft Nude Mice

SiRNA-circFARSA-loaded porous silicon nanomaterials for pancreatic cancer treatment via inhibition of CircFARSA expression